Open Access<p>A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following COVID-19 Pneumonia – Case Reports</p>
Author(s) -
Chiara Scelfo,
Matteo Fontana,
Eleonora Casalini,
Francesco Menzella,
Roberto Piro,
Alessandro Zerbini,
Lucia Spaggiari,
Luca Ghidorsi,
Giulia Ghidoni,
Nicola Facciolongo
Publication year - 2020
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s275779
Subject(s) - medicine , pneumonia , ards , diffuse alveolar damage , lung , pulmonary fibrosis , viral pneumonia , etiology , intensive care medicine , covid-19 , pandemic , outbreak , pathological , pediatrics , disease , pathology , infectious disease (medical specialty) , acute respiratory distress
The outbreak of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) started in China in December 2019. COVID-19 patients at presentation show a wide spectrum of clinical and pathological involvement. We report two cases of respiratory insufficiency due to COVID-19 pneumonia that occurred in adults without a history of respiratory diseases. Although these patients improved and were discharged from the acute ward, during the hospitalization they both progressed with a subsequent clinical and radiological worsening, pointing out one of the main concerns for these patients at discharge: the possibility of developing persistent lung abnormalities also in healthy people not having other risk factors. In conclusion, these cases represent two examples of early lung fibrosis in patients with COVID-19 pneumonia with different severity disease evolution and highlight the need for long-term follow-up strategies. The etiology of this fibrosis is under discussion: we suppose that it could be due to either a possible outcome of natural history of lung damage produced by ARDS, or to the lung injury related to high oxygen level or to the lung damage directly induced by viral infection or finally to the autoimmune response. At this moment, it is not possible to predict how many people will have consequences due to COVID-19 pneumonia, and therefore we believe that careful follow-up should be mandatory.